ALX/FPR2 (also known as ALXR or Lipoxin A4 receptor/Formyl Peptide Receptor 2) is a G-protein coupled receptor that serves as the primary receptor for specialized pro-resolving mediators (SPMs), particularly lipoxins and resolvins. This receptor acts as a molecular "switch" that transitions inflammatory responses from pro-inflammatory signaling to active resolution, making it a critical node in the immune system's ability to return to homeostasis after threat response.
Think of ALX/FPR2 as a sophisticated doorbell system on an immune cell's front door that can recognize two very different types of visitors. Early in an emergency (infection, injury), it responds to bacterial alarm signals—like a doorbell ringing for the fire department—activating pro-inflammatory defenses. But once the threat is contained, the same doorbell starts recognizing a completely different set of callers: the "clean-up crew" molecules like lipoxins and resolvins. When these resolution mediators ring the bell, the receptor switches the entire cellular program from "attack mode" to "repair and restore mode." It's the same receptor, same door, but depending on who's ringing (bacterial peptides versus resolvins), you get firefighters or renovation contractors. This dual personality makes ALX/FPR2 one of the most important checkpoints in determining whether inflammation burns itself out productively or spirals into chronic dysfunction.
ALX/FPR2 operates through distinct ligand-dependent signaling cascades:
Pro-inflammatory activation (early phase):
- Bacterial formyl-peptides (fMLF) or serum amyloid A (SAA) bind ALX/FPR2
- Gαi protein coupling → phospholipase C activation
- IP3/DAG second messengers → Ca²⁺ mobilization
- MAPK/ERK and NF-κB activation
- Neutrophil chemotaxis, oxidative burst, degranulation
Pro-resolving activation (resolution phase):
- Lipoxin A4 (LXA4), resolvin D1 (RvD1), or annexin A1 bind ALX/FPR2
- Different conformational change triggers β-arrestin-biased signaling
- SOCS3 upregulation → suppression of NF-κB
- PI3K/Akt pathway activation → phagocytosis enhancement
- ERK1/2 phosphorylation → apoptotic neutrophil clearance (efferocytosis)
- PPAR-γ activation → M2 macrophage polarization
- Reduced ROS production, decreased adhesion molecule expression
graph TD
A[ALX/FPR2 Receptor] -->|"Early: fMLF/SAA"| B["Gαi Coupling"]
A -->|"Late: LXA4/RvD1"| C["β-Arrestin Signaling"]
B --> D[PLC Activation]
D --> E["Ca²⁺ Mobilization"]
E --> F["Pro-inflammatory: Chemotaxis, ROS, Degranulation"]
C --> G[SOCS3 Upregulation]
G --> H["NF-κB Suppression"]
C --> I[PI3K/Akt Activation]
I --> J[Enhanced Efferocytosis]
C --> K["PPAR-γ Activation"]
K --> L[M2 Polarization]
F -.->|Time/SPM accumulation| C
style A fill:#e1f5ff
style F fill:#ffcccc
style L fill:#ccffcc
Ligand biased signaling:
The same receptor produces opposite outcomes depending on ligand structure and concentration. Low-dose LXA4 (0.1-1 nM) triggers resolution pathways; high-dose bacterial peptides overwhelm this with pro-inflammatory cascades. The receptor's ability to "read" the chemical context determines inflammatory fate.
Clinical threshold: ALX/FPR2 expression increases 3-5 fold during active resolution (24-72 hours post-injury). Failure to upregulate correlates with chronic inflammatory states.
ALX/FPR2 represents a critical intervention target in cPNI practice because it is the primary receptor translating Specialized pro-resolving mediators (SPMs) into cellular action. When this receptor system fails—through genetic polymorphisms, receptor desensitization, or insufficient SPM production—inflammation cannot resolve, regardless of how much acute defense was appropriate.
Metamodel connections:
- Metamodel 3 (Time/Rhythm): ALX/FPR2 activation must follow circadian and injury-phase timing. Resolution signals (LXA4, RvD1) only become effective 12-24 hours after initial injury; premature administration may interfere with pathogen clearance
- Selfish Immune System: ALX/FPR2 is the mechanism by which the immune system "agrees" to stand down—but only if it detects sufficient resolution mediators, indicating the threat is truly resolved
Clinical conditions with ALX/FPR2 dysfunction:
Intervention implications:
- Timing matters: SPM supplementation (EPA, DHA, specialized pro-resolving mediator cocktails) is most effective 12-48 hours post-injury, when ALX/FPR2 expression peaks
- Receptor sensitization: Vitamin D, Curcumin, and Omega-3 fatty acids upregulate ALX/FPR2 expression
- Avoid receptor antagonism: High-dose NSAIDs during resolution phase can block ALX/FPR2 signaling
- Consider genetic variation: ALX/FPR2 polymorphisms (rs867228) reduce ligand affinity; may require higher-dose SPM therapy
Biomarkers of ALX/FPR2 function:
- Lipoxin A4 levels <100 pg/mL → inadequate resolution capacity
- RvD1 <50 pg/mL → chronic inflammatory risk
- High CRP (>10 mg/L) + low SPMs = resolution failure phenotype
- ALX/FPR2 binds >20 different ligands with opposing functional outcomes (pro-inflammatory peptides vs. pro-resolving lipids)
- Receptor expression increases 3-5 fold during active resolution (24-72 hours post-injury)
- Beta-arrestin-biased signaling (triggered by LXA4/RvD1) bypasses pro-inflammatory Gαi pathways
- ALX/FPR2 activation reduces neutrophil infiltration by 60-80% in resolution phase
- Receptor half-life on cell membrane: 20-30 minutes; requires continuous ligand supply
- Aspirin acetylates COX-2, shifting arachidonic acid metabolism toward 15-epi-LXA4 (aspirin-triggered lipoxin), which binds ALX/FPR2
- ALX/FPR2 knockout mice develop spontaneous arthritis and delayed wound healing
- Receptor density highest on: neutrophils, monocytes, macrophages, endothelial cells, adipocytes
- Glucocorticoid Receptor activation upregulates ALX/FPR2 expression via annexin A1 induction
- Chronic Hyperglycaemia (HbA1c >7%) glycates ALX/FPR2, reducing ligand binding affinity by 40-60%
- Resolution phase begins when RvD1:LTB4 ratio >1:5 and ALX/FPR2 activation exceeds TLR4 signaling
- ALX/FPR2 — this is the primary entry; see full description there
- Specialized pro-resolving mediators (SPMs) — primary ligands that activate resolution signaling via ALX/FPR2
- Lipoxin A4 — first identified pro-resolving ALX/FPR2 agonist; produced via 15-LOX pathway
- Resolvin D1 — high-affinity ALX/FPR2 ligand derived from DHA; triggers efferocytosis
- Aspirin-triggered lipoxins — 15-epi-LXA4 produced when aspirin modifies COX-2; binds ALX/FPR2
- Resolvins — family of DHA/EPA-derived ALX/FPR2 agonists that terminate neutrophil infiltration
- Efferocytosis — ALX/FPR2 activation enhances macrophage clearance of apoptotic cells via PI3K/Akt
- Resolution of inflammation — ALX/FPR2 is the principal receptor orchestrating active resolution programs
- NF-κB — ALX/FPR2 resolution signaling suppresses NF-κB via SOCS3 upregulation
- SOCS3 — induced by ALX/FPR2 ligation with resolvins; blocks STAT3 and NF-κB pro-inflammatory cascades
- Macrophage Polarization — ALX/FPR2 signaling drives M2 phenotype via PPAR-γ activation
- Neutrophil — express highest density of ALX/FPR2; receptor controls chemotaxis termination and apoptosis
- Chronic inflammation — persistent ALX/FPR2 dysfunction prevents resolution, perpetuating inflammatory disease
- DHA — metabolic precursor for RvD1 and other D-series resolvins that activate ALX/FPR2
- EPA — precursor for E-series resolvins binding ALX/FPR2
- COX-2 — acetylated by aspirin to produce 15-epi-lipoxins that activate ALX/FPR2
- Annexin A1 — glucocorticoid-induced protein that activates ALX/FPR2 to suppress inflammation
- TLR4 — pro-inflammatory receptor whose signaling must be overcome by ALX/FPR2 for resolution
- Inflammatory resolution — ALX/FPR2 is the master switch transitioning from inflammation to repair
- Metaflammation — adipose tissue ALX/FPR2 suppression contributes to metabolic inflammation
- Omega-3 fatty acids — dietary substrate for SPM synthesis and direct ALX/FPR2 upregulation
- NSAIDs — can interfere with SPM production but aspirin uniquely generates ALX/FPR2 agonists
- Glucocorticoid Receptor — cortisol induces annexin A1, which activates ALX/FPR2 as part of HPA resolution signaling
- Vitamin D — upregulates ALX/FPR2 expression in monocytes and macrophages
- Curcumin — enhances ALX/FPR2 expression and sensitizes receptor to resolvins